DiscGenics Raises $14 Million in Series B Financing

SALT LAKE CITY, Sept. 26, 2017 -- (Healthcare Sales & Marketing Network) -- DiscGenics, Inc., a clinical stage regenerative medicine company focused on developing regenerative therapies that alleviate pain and restore function in patients with degenerativ... Regenerative Medicine, Orthopaedic, Venture Capital DiscGenics, cell therapy, degenerative disc disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news